佛慈制药
(002644)
| 流通市值：39.98亿 | | | 总市值：39.98亿 |
| 流通股本：5.11亿 | | | 总股本：5.11亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 216,124,672.92 | 980,225,387.73 | 708,531,496.45 | 498,880,666.79 |
| 营业收入 | 216,124,672.92 | 980,225,387.73 | 708,531,496.45 | 498,880,666.79 |
| 二、营业总成本 | 189,743,028.4 | 903,743,257.88 | 651,587,799.98 | 449,707,132.77 |
| 营业成本 | 142,041,673.69 | 680,513,278.37 | 481,626,455.52 | 334,865,307.01 |
| 税金及附加 | 3,945,047.38 | 14,095,061.43 | 9,996,270.2 | 6,564,789.41 |
| 销售费用 | 20,231,809.02 | 116,044,604.78 | 93,057,848.76 | 61,675,351.75 |
| 管理费用 | 16,347,923.44 | 68,957,995.3 | 49,498,710.96 | 34,631,847.18 |
| 研发费用 | 7,741,713.66 | 29,284,084.57 | 21,768,633.09 | 14,621,828.52 |
| 财务费用 | -565,138.79 | -5,151,766.57 | -4,360,118.55 | -2,651,991.1 |
| 其中:利息费用 | - | 831,438.63 | 973,583.61 | 415,446.8 |
| 其中:利息收入 | - | 5,743,444.14 | 5,445,098.27 | 3,102,880.85 |
| 加:投资收益 | -1,015,474.66 | -7,233,165.17 | -6,521,859.04 | -3,411,896.2 |
| 资产处置收益 | 1,415.92 | 40,438.07 | 11,680.13 | 11,680.13 |
| 资产减值损失(新) | - | -151,744.5 | -17,690.4 | -17,690.4 |
| 信用减值损失(新) | -8,024,525.12 | -33,666,912.41 | -21,135,076.43 | -13,809,188.51 |
| 其他收益 | 5,568,578.12 | 34,974,982.54 | 17,037,926.07 | 10,311,672.8 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 22,911,638.78 | 70,445,728.38 | 46,318,676.8 | 42,258,111.84 |
| 加:营业外收入 | 894,830.1 | 435,595.54 | 32,958.97 | 4,378.46 |
| 减:营业外支出 | 73,627.47 | 1,741,820.55 | 679,810.7 | 470,843.24 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 23,732,841.41 | 69,139,503.37 | 45,671,825.07 | 41,791,647.06 |
| 减:所得税费用 | 3,608,602.78 | 7,473,892.6 | 5,223,143.28 | 4,727,792.12 |
| 六、净利润 | 20,124,238.63 | 61,665,610.77 | 40,448,681.79 | 37,063,854.94 |
| 持续经营净利润 | 20,124,238.63 | 61,665,610.77 | 40,448,681.79 | 37,063,854.94 |
| 归属于母公司股东的净利润 | 19,381,644.03 | 60,069,813.05 | 39,072,938.02 | 36,095,275.18 |
| 少数股东损益 | 742,594.6 | 1,595,797.72 | 1,375,743.77 | 968,579.76 |
| (一)基本每股收益 | 0.04 | 0.12 | 0.08 | 0.07 |
| (二)稀释每股收益 | 0.04 | 0.12 | 0.08 | 0.07 |
| 八、其他综合收益 | - | 130,949.54 | 487,793.63 | 496,374.73 |
| 归属于母公司股东的其他综合收益 | - | 68,427.66 | 251,518.59 | 255,943.22 |
| 九、综合收益总额 | 20,124,238.63 | 61,796,560.31 | 40,936,475.42 | 37,560,229.67 |
| 归属于母公司股东的综合收益总额 | 19,381,644.03 | 60,138,240.71 | 39,324,456.61 | 36,351,218.4 |
| 归属于少数股东的综合收益总额 | 742,594.6 | 1,658,319.6 | 1,612,018.81 | 1,209,011.27 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |